Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Marcus R et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first line treatment for advanced follicular lymphoma. Blood 105: 1417–1423

    Article  CAS  Google Scholar 

  2. Forstpointner R et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood 104: 3064–3071

    Article  CAS  Google Scholar 

  3. Hiddemann W et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 106: 3725–3732

    Article  CAS  Google Scholar 

  4. van Oers MH et al. (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomised phase 3 intergroup trial. Blood 108: 3295–3301

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ritchie, D. Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?. Nat Rev Clin Oncol 4, 402–403 (2007). https://doi.org/10.1038/ncponc0842

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0842

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing